| Drug Name |
Target |
Source |
Route of administration |
FDA-approved indication |
FDA pregnancy category |
Bioavailability |
Elimination half-life (days) |
Volume of distribution |
Dosage for IBD |
| Adalimumab[14] |
TNFα |
Humana |
SC |
IBD, RAd, psoriasis, ankylosing spondylitis |
B |
64% |
14 |
4.7-6 L |
Day 1: 4 x 40 mg injections in one day or 2 x 40 mg injections per day for two consecutive days
Day 15: 80 mg
Day 29: a maintenance dose of 40 mg every other week. |
| Certolizumabpegol [15] |
TNFα |
Humanizedb |
SC |
IBD |
B |
76-88% |
14 |
6-8 L |
400 mg at 0, 2, and 4 weeks. If response occurs, follow with 400 mg every four weeks |
| Golimumab[16] |
TNFα |
Humana |
SC |
UC, RA, psoriatic arthritis, ankylosing spondylitis |
B |
53% |
14 |
58-126 ml/kg |
200 mg at week 0, followed by 100 mg at week 2, then 100 mg every four weeks |
| Infliximab [17] |
TNFα |
Chimericc |
IV |
IBD, RA, psoriasis, ankylosing spondylitis |
B |
- |
7-12 |
3-6 L |
5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks |
| Natalizumab[18] |
α4-integrin |
Humanizedb |
IV |
CD, multiple sclerosis |
C |
- |
3-17 |
~5 L |
300 mg IV infusion over 1hr every 4 weeks |
| aEntirely human amino acids; bContaining murine CDRs; cComposed of human constant and murine variable regions; d Rheumatoid arthritis |
|
|
